Antje Habel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antje Habel has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Felix Sahm
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
4 shared publications - Philipp Sievers
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
3 shared publications - Wolfgang Wick
Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
3 shared publications - Adelheid Woehrer
Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria
2 shared publications - Andreas von Deimling
Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany
2 shared publications Areeba Patel
Division of AI in Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 884-898
Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes
Molecular testing is essential for classifying central nervous system (CNS) tumors, with methylation profiling providing the highest diagnostic granularity. However, this requires more resources and time than conventional hematoxylin and eosin (H&E) histopathology, which is widely available globally. Here we propose Hetairos, an artificial intelligence algorithm that predicts 102 methylation-based CNS tumor subtypes from digital H&E slides. Built and validated on 9,606 patients and over 11,000 slides from 11 centers across four continents, Hetairos identified 50–70% of cases with high confidence, achieving an accuracy of 0.87 for its highest-rated predictions. Hetairos outperformed five board-certified neuropathologists in a direct histology-only comparison (0.68 versus 0.30). Prospective evaluation in routine diagnostics confirmed its performance, reducing turnaround time from 12 days (molecular testing) to 12 min. Hetairos supports diagnostic decision-making across the full spectrum of pediatric and adult CNS tumors by narrowing differential diagnoses and guiding efficient testing.
- 10 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 884-898
Open AccessHetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes
Molecular testing is essential for classifying central nervous system (CNS) tumors, with methylation profiling providing the highest diagnostic granularity. However, this requires more resources and time than conventional hematoxylin and eosin (H&E) histopathology, which is widely available globally. Here we propose Hetairos, an artificial intelligence algorithm that predicts 102 methylation-based CNS tumor subtypes from digital H&E slides. Built and validated on 9,606 patients and over 11,000 slides from 11 centers across four continents, Hetairos identified 50–70% of cases with high confidence, achieving an accuracy of 0.87 for its highest-rated predictions. Hetairos outperformed five board-certified neuropathologists in a direct histology-only comparison (0.68 versus 0.30). Prospective evaluation in routine diagnostics confirmed its performance, reducing turnaround time from 12 days (molecular testing) to 12 min. Hetairos supports diagnostic decision-making across the full spectrum of pediatric and adult CNS tumors by narrowing differential diagnoses and guiding efficient testing.
- Open Access
- 13 January 2025
- Published by Springer Nature in Research Square
AI-based histopathological classification of central nervous system tumours
DNA methylation analysis has become an essential diagnostic assay for classifying tumours of the central nervous system (CNS). However, this test requires additional resources and time compared to conventional histopathological diagnosis using haematoxylin and eosin (H&E) stained tissue sections, which are available globally. Here, we propose to reduce time and resource requirements using Hetairos, an artificial intelligence (AI) algorithm that predicts 102 methylation-based CNS tumour subtypes from digital images of H&E slides. Hetairos is built and assessed using over 11,000 slides from 10 centres across four continents. Hetairos produces well-calibrated probabilities for each subtype. Across cohorts, Hetairos identifies 50-70% of cases, which it classifies with high confidence and an accuracy of 0.87 for its highest-rated predictions. Hetairos achieved higher accuracy than four board-certified neuropathologists in a direct comparison using only histology images (0.68 vs 0.28). A prospective evaluation within a routine diagnostic setting confirmed Hetairos’ performance and highlighted its 2-day turnaround time compared to an average of 12 days for molecular testing. Hetairos can assist diagnostic decision-making by limiting the number of likely diagnoses, informing efficient further testing, and by highlighting tissue areas indicative of specific diagnoses. These capabilities suggest Hetairos is a valuable tool assisting in the diagnosis of the full spectrum of paediatric and adult CNS tumours.
- 13 January 2025
- Published by Springer Nature in Research Square
Open AccessAI-based histopathological classification of central nervous system tumours
DNA methylation analysis has become an essential diagnostic assay for classifying tumours of the central nervous system (CNS). However, this test requires additional resources and time compared to conventional histopathological diagnosis using haematoxylin and eosin (H&E) stained tissue sections, which are available globally. Here, we propose to reduce time and resource requirements using Hetairos, an artificial intelligence (AI) algorithm that predicts 102 methylation-based CNS tumour subtypes from digital images of H&E slides. Hetairos is built and assessed using over 11,000 slides from 10 centres across four continents. Hetairos produces well-calibrated probabilities for each subtype. Across cohorts, Hetairos identifies 50-70% of cases, which it classifies with high confidence and an accuracy of 0.87 for its highest-rated predictions. Hetairos achieved higher accuracy than four board-certified neuropathologists in a direct comparison using only histology images (0.68 vs 0.28). A prospective evaluation within a routine diagnostic setting confirmed Hetairos’ performance and highlighted its 2-day turnaround time compared to an average of 12 days for molecular testing. Hetairos can assist diagnostic decision-making by limiting the number of likely diagnoses, informing efficient further testing, and by highlighting tissue areas indicative of specific diagnoses. These capabilities suggest Hetairos is a valuable tool assisting in the diagnosis of the full spectrum of paediatric and adult CNS tumours.
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (95) , eadj7970
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance
Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory “checkpoint molecules,” such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell–intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6 + T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor–treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell–dependent immune checkpoint that regulates human T cell function.
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (95) , eadj7970
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance
Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory “checkpoint molecules,” such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell–intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6 + T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor–treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell–dependent immune checkpoint that regulates human T cell function.
- Top Cited Papers
- 14 December 2022
- Published by Springer Nature in Nature
- Vol. 613 (7942) , 179-186
Autonomous rhythmic activity in glioma networks drives brain tumour growth
Diffuse gliomas, particularly glioblastomas, are incurable brain tumours1. They are characterized by networks of interconnected brain tumour cells that communicate via Ca2+ transients2,3,4,5,6. However, the networks’ architecture and communication strategy and how these influence tumour biology remain unknown. Here we describe how glioblastoma cell networks include a small, plastic population of highly active glioblastoma cells that display rhythmic Ca2+ oscillations and are particularly connected to others. Their autonomous periodic Ca2+ transients preceded Ca2+ transients of other network-connected cells, activating the frequency-dependent MAPK and NF-κB pathways. Mathematical network analysis revealed that glioblastoma network topology follows scale-free and small-world properties, with periodic tumour cells frequently located in network hubs. This network design enabled resistance against random damage but was vulnerable to losing its key hubs. Targeting of autonomous rhythmic activity by selective physical ablation of periodic tumour cells or by genetic or pharmacological interference with the potassium channel KCa3.1 (also known as IK1, SK4 or KCNN4) strongly compromised global network communication. This led to a marked reduction of tumour cell viability within the entire network, reduced tumour growth in mice and extended animal survival. The dependency of glioblastoma networks on periodic Ca2+ activity generates a vulnerability7 that can be exploited for the development of novel therapies, such as with KCa3.1-inhibiting drugs.
- 14 December 2022
- Published by Springer Nature in Nature
- Vol. 613 (7942) , 179-186
Top Cited PapersAutonomous rhythmic activity in glioma networks drives brain tumour growth
Diffuse gliomas, particularly glioblastomas, are incurable brain tumours1. They are characterized by networks of interconnected brain tumour cells that communicate via Ca2+ transients2,3,4,5,6. However, the networks’ architecture and communication strategy and how these influence tumour biology remain unknown. Here we describe how glioblastoma cell networks include a small, plastic population of highly active glioblastoma cells that display rhythmic Ca2+ oscillations and are particularly connected to others. Their autonomous periodic Ca2+ transients preceded Ca2+ transients of other network-connected cells, activating the frequency-dependent MAPK and NF-κB pathways. Mathematical network analysis revealed that glioblastoma network topology follows scale-free and small-world properties, with periodic tumour cells frequently located in network hubs. This network design enabled resistance against random damage but was vulnerable to losing its key hubs. Targeting of autonomous rhythmic activity by selective physical ablation of periodic tumour cells or by genetic or pharmacological interference with the potassium channel KCa3.1 (also known as IK1, SK4 or KCNN4) strongly compromised global network communication. This led to a marked reduction of tumour cell viability within the entire network, reduced tumour growth in mice and extended animal survival. The dependency of glioblastoma networks on periodic Ca2+ activity generates a vulnerability7 that can be exploited for the development of novel therapies, such as with KCa3.1-inhibiting drugs.